Kadmon Competitors and Similar CompaniesClear all
Kadmon's competitors and similar companies include G1 Therapeutics, Reata Pharmaceuticals, Pliant Therapeutics and Lee's Pharm.
 Kadmon Kadmon Corporation is a biopharmaceutical company offering products and services for the treatment and management of hepatitis C. |  G1 Therapeutics G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. |  Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. |  Pliant Therapeutics Pliant Therapeutics is a company focused on discovering, developing, and commercializing treatments for fibrotic diseases. |  Lee's Pharm Lee's Pharm (Lee's Pharmaceutical Holdings) is a company that develops, manufactures, and sells biopharmaceutical products for cardiovascular and infectious diseases areas. | |
Founding Date | Founding Date 2010 | Founding Date 2008 | Founding Date 2002 | Founding Date 2016 | Founding Date 1994 |
Type | Type Subsidiary | Type Public | Type Public | Type Private | Type Public |
Tags | |||||
Locations | Locations New York, US HQ Cambridge, US South Brunswick Township, US Warrendale, US | Locations Durham, US HQ | Locations Plano, US HQ Irving, US Plano, US | Locations South San Francisco, US HQ | Locations Hong Kong, HK HQ Taipei, TW |
Employees | Employees 44 | Employees 17015% increase | Employees 3217% decrease | Employees 1519% decrease | Employees 1,022 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 377.2 m | Valuation ($) 6.6 b | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $8.3m (FY, 2020) | Revenue (est.) $82.5m (FY, 2023) | Revenue (est.) $2.2m (FY, 2022) | Revenue (est.) N/A | Revenue (est.) $1.4b (FY, 2024) |
Cost of goods | Cost of goods N/A | Cost of goods $7.2m (FY, 2023) | Cost of goods N/A | Cost of goods N/A | Cost of goods $498.9m (FY, 2024) |
Gross profit | Gross profit N/A | Gross profit $75.3m (FY, 2023) | Gross profit N/A | Gross profit N/A | Gross profit $961.4m (FY, 2024) |
Net income | Net income ($108.9m) (FY, 2020) | Net income ($48m) (FY, 2023) | Net income ($311.9m) (FY, 2022) | Net income N/A | Net income $68.6m (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised $ 21.3m | Total funding raised $ 289.6m | Total funding raised $ 468.9m | Total funding raised $ 107m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
G1 Therapeutics
HQ
Durham, US
Employees
170↑ 15% increase
G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer.
View companyReata Pharmaceuticals
HQ
Plano, US
Employees
321↓ 7% decrease
Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.
View companyPliant Therapeutics
HQ
South San Francisco, US
Employees
151↓ 9% decrease
Pliant Therapeutics is a company focused on discovering, developing, and commercializing treatments for fibrotic diseases.
View companyLee's Pharm
HQ
Hong Kong, HK
Employees
1,022
Lee's Pharm (Lee's Pharmaceutical Holdings) is a company that develops, manufactures, and sells biopharmaceutical products for cardiovascular and infectious diseases areas.
View company